Hologic to Sell Blood-Screening Business to Grifols for USD 1.85 Billion
|
By LabMedica International staff writers Posted on 15 Dec 2016 |
|
US medical device maker Hologic, Inc. (Bedford, MA, USA) has agreed to sell off its share of the Procleix blood-screening business to long-time partner, Grifols SA (Barcelona, Spain), for USD 1.85 billion in cash.
Hologic develops, manufactures, and supplies diagnostic products, medical imaging systems, and surgical products. The company's core business units focus on diagnostics, breast health, gynecological surgery, and skeletal health. Since 1998, Hologic has worked with Grifol, which develops plasma protein therapies, to develop their blood-screening business.
The Procleix blood-screening business offers molecular assays and instruments to blood banks for screening donated blood, prior to transfusion, for viruses including HIV, hepatitis C and B, West Nile and Zika. Hologic handles research and development and manufacturing of the Procleix blood-screening products, while Grifols is responsible for selling the molecular assays and instruments.
As per the deal, which has been approved by boards of both the companies, Grifols will acquire Hologic's blood-screening manufacturing facility in Rancho Bernardo, California, as well as the development rights, licenses to patents and access to product manufacturers. Hologic will retain the engineering expertise associated with the blood-screening systems including Tigris and Panther, but will continue to work with Grifols to ensure that its customers have access to its blood-screening instruments over the long-term.
"Divesting our share of our blood screening business to Grifols will strengthen our efforts to build a sustainable growth company by accelerating top- and bottom-line growth rates, while significantly increasing financial flexibility," said Hologic’s chairman, president and CEO, Steve MacMillan. "We are immensely proud of the contributions we have made to global blood safety over nearly 20 years. But at the same time, we believe that the business and our blood screening employees are best positioned to succeed under a single owner, and that this sale to Grifols provides excellent value for Hologic and our shareholders."
Related Links:
Hologic
Grifols
Hologic develops, manufactures, and supplies diagnostic products, medical imaging systems, and surgical products. The company's core business units focus on diagnostics, breast health, gynecological surgery, and skeletal health. Since 1998, Hologic has worked with Grifol, which develops plasma protein therapies, to develop their blood-screening business.
The Procleix blood-screening business offers molecular assays and instruments to blood banks for screening donated blood, prior to transfusion, for viruses including HIV, hepatitis C and B, West Nile and Zika. Hologic handles research and development and manufacturing of the Procleix blood-screening products, while Grifols is responsible for selling the molecular assays and instruments.
As per the deal, which has been approved by boards of both the companies, Grifols will acquire Hologic's blood-screening manufacturing facility in Rancho Bernardo, California, as well as the development rights, licenses to patents and access to product manufacturers. Hologic will retain the engineering expertise associated with the blood-screening systems including Tigris and Panther, but will continue to work with Grifols to ensure that its customers have access to its blood-screening instruments over the long-term.
"Divesting our share of our blood screening business to Grifols will strengthen our efforts to build a sustainable growth company by accelerating top- and bottom-line growth rates, while significantly increasing financial flexibility," said Hologic’s chairman, president and CEO, Steve MacMillan. "We are immensely proud of the contributions we have made to global blood safety over nearly 20 years. But at the same time, we believe that the business and our blood screening employees are best positioned to succeed under a single owner, and that this sale to Grifols provides excellent value for Hologic and our shareholders."
Related Links:
Hologic
Grifols
Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
New
Benchtop Thermomixer
Biometra TS1 ThermoShaker
New
Repetitive Pipette
VWR® Stepper Pro
Latest Industry News
- Co-Diagnostics Agreement Expands Commercial and Distribution Reach in South Asia
- Automated MSI Test Gains IVDR Certification to Guide CRC Therapy
- New Partnership Brings Alzheimer’s Blood Biomarker Test to Community Screening Network
- MGI Tech Strengthens Sequencing Portfolio with Dual Acquisition
- Agilent Technologies Acquires Pathology Diagnostics Company Biocare Medical
- Cepheid Joins CDC Initiative to Strengthen U.S. Pandemic Testing Preparednesss
- QuidelOrtho Collaborates with Lifotronic to Expand Global Immunoassay Portfolio
- WHX Labs in Dubai spotlights leadership skills shaping next-generation laboratories
- AI-Powered Cervical Cancer Test Set for Major Rollout in Latin America
- New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing
- Diasorin and Fisher Scientific Enter into US Distribution Agreement for Molecular POC Platform
- WHX Labs Dubai to Gather Global Experts in Antimicrobial Resistance at Inaugural AMR Leaders’ Summit
- BD and Penn Institute Collaborate to Advance Immunotherapy through Flow Cytometry
- Abbott Acquires Cancer-Screening Company Exact Sciences
- Roche and Freenome Collaborate to Develop Cancer Screening Tests
- Co-Diagnostics Forms New Business Unit to Develop AI-Powered Diagnostics
Channels
Clinical Chemistry
view channel
CSF Biomarker Improves Diagnosis of Parkinson’s Disease and Lewy Body Dementia
Parkinson’s disease and dementia with Lewy bodies are frequently misdiagnosed, often being confused with Alzheimer’s disease because of overlapping symptoms. Objective diagnostics for these synucleinopathies... Read more
Simple Urine Home Test Kit Could Detect Early-Stage Breast Cancer
Breast cancer is the most commonly diagnosed cancer among women globally and remains a leading cause of cancer-related deaths in more than 100 countries. Current diagnostic pathways rely on mammography,... Read more
Molecular Diagnostics
view channel
Blood Biomarker Predicts Cognitive Outcomes After Cardiac Arrest
Long-term cognitive impairment is a frequent consequence of out-of-hospital cardiac arrest yet early prediction remains difficult. Clinicians commonly use blood-based markers to estimate brain injury risk... Read more
Liquid Biopsy Enables Faster Diagnosis of Childhood Cancer in Africa
Burkitt lymphoma is the most common childhood cancer in Africa and progresses rapidly, making fast, accurate diagnosis essential to survival. Although survival can exceed 90% when therapy starts quickly,... Read more
Hematology
view channel
Rapid Cartridge-Based Test Aims to Expand Access to Hemoglobin Disorder Diagnosis
Sickle cell disease and beta thalassemia are hemoglobin disorders that often require referral to specialized laboratories for definitive diagnosis, delaying results for patients and clinicians.... Read more
New Guidelines Aim to Improve AL Amyloidosis Diagnosis
Light chain (AL) amyloidosis is a rare, life-threatening bone marrow disorder in which abnormal amyloid proteins accumulate in organs. Approximately 3,260 people in the United States are diagnosed... Read more
Immunology
view channel
Microfluidic Chip Detects Cancer Recurrence from Immune Response Signals
Early identification of treatment response and relapse remains a major challenge in solid tumors, where minimal residual disease is difficult to detect with routine imaging and blood tests.... Read more
Cancer Mutation ‘Fingerprints’ to Improve Prediction of Immunotherapy Response
Cancer cells accumulate thousands of genetic mutations, but not all mutations affect tumors in the same way. Some make cancer cells more visible to the immune system, while others allow tumors to evade... Read more
Microbiology
view channel
Breath Analysis Approach Offers Rapid Detection of Bacterial Infection
Accurate and rapid identification of bacterial infections remains challenging in acute care, where delays can hinder timely, targeted therapy. Infectious diseases are a major cause of mortality worldwide,... Read more
Study Highlights Accuracy Gaps in Consumer Gut Microbiome Kits
Direct-to-consumer gut microbiome kits promise personalized insights by profiling fecal bacteria and generating health readouts, but their analytical accuracy remains uncertain. A new study shows that... Read more
WHO Recommends Near POC Tests, Tongue Swabs and Sputum Pooling for TB Diagnosis
Tuberculosis (TB) remains one of the world’s leading infectious disease killers, yet millions of cases go undiagnosed or are detected too late. Barriers such as reliance on sputum samples, limited laboratory... Read more
Pathology
view channel
AI-Powered Tool to Transform Dermatopathology Workflow
Skin cancer accounts for the largest number of cancer diagnoses in the United States, placing sustained pressure on pathology services. Diagnostic interpretation can be variable for challenging melanocytic... Read more
New Chromogenic Culture Media Enable Rapid Detection of Candida Infections
Invasive Candida infections are challenging for healthcare systems, with some strains spreading rapidly in hospitals and showing resistance to multiple antifungal drugs. Candida auris is associated with... Read more
Technology
view channel
Portable Breath Sensor Detects Pneumonia Biomarkers in Minutes
Pneumonia is commonly confirmed with chest X-rays or laboratory assays that can take hours, delaying clinical decisions in acute and outpatient settings. Breath-based diagnostics promise faster answers... Read more
New Electronic Pipette Enhances Workflows with Touchscreen Control
Manual pipetting remains a routine yet error-prone step that can affect reproducibility and throughput in clinical and research laboratories. Training demands and ergonomic strain also add variability... Read more
AI Model Outperforms Clinicians in Rare Disease Detection
Rare diseases affect an estimated 300 million people worldwide, yet diagnosis is often protracted and error-prone. Many conditions present with heterogeneous signs that overlap with common disorders, leading... Read more
